The FDA has repeatedly asserted in its summary reviews of the four exon-skipping drugs granted accelerated approval that the role of dystrophin is well-characterized in the pathophysiology of DMD.20–23 Dystrophin is a critical muscle protein that is reduced or absent in DMD patients. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.